Chinese

Colorectal CancerClinical Solutions

Home>Clinical Solutions>Cancer>Colorectal Cancer

Early Screening Recurrence Risk Companion Diagnosis Toxicity Evaluation Drug Resistance Technology Platform Service Protocol
Early Screening

ColoPredict:   Based on gene chip or PCR technology to detect 37SNPs, as well as algorithm to assess the genetic susceptibility of colorectal cancer, one test through lifetime. 

1493706400479151PwxC.jpgThe 5 year survival rate of colorectal cancer in China is only ~30%, while in the United States, up to 65%, because most of the patients in China were diagnosed as stage III-IV.Detection of genetic susceptibility in high risk poupulations is lacking in practice.   

1493706400479151PwxC.jpg Test developed by Oxford Cancer Biomarkers company , former ESMO chairman David Kerr is involved. It has been validated in the N=47000 healthy population, and demonstrated that high risk group will have 3.5 times risk of developing CRC compared with low risk group within a period of 10 years.  

1493706400479151PwxC.jpgColorectal cancer is lifestyle related.  Screened high-risk groups can enter further examination, such as ColoGuide, colonoscopy, to achieve early diagnosis. High-risk groups can also reduce the proportion of colorectal cancer development  through lifestyle changing.

Recurrence Risk

ColoProg:  Based on digital pathology -Ploidy and Stroma, as well as algorithms, to provide stage II patients with colorectal cancer recurrence risk prediction, suggesting whether  individual patients need adjuvant therapy.                                       

1493706400479151PwxC.jpg Currently, there is a lack of an effective risk assessment method for patients with stage II colorectal cancer to determine whether individual patient need adjuvant therapy after radical operation, and the NCCN guidelines are also controversial for some patients to be treated with adjuvant chemotherapy. 

1493706400479151PwxC.jpgThe guideline currently recommends for MSI/MMR, but unfortunately the detection rate in sporadic colorectal cancer is only ~10%.

1493706400479151PwxC.jpgPatients with stage II colorectal cancer after surgery, who are at low risk of recurrence by ColoProg, may be able to avoid unnecessary chemotherapy and radiotherapy, and high-risk patients with ColoProg will require adjuvant therapy after surgery.   

1493706400479151PwxC.jpgTest developed by Oxford Cancer Biomarkers company , in which former ESMO chairman David Kerr is involved.Based on the study of QUASAR2 (adjuvant treatment of Capecitabine and Bevacizumab) in tissue samples of II patients (radical resection, no evidence of residual disease, N=1074), verification of ColoProg HR=3.5, better than Oncotype DxColon (HR=1.7).

Companion Diagnosis

Ai keyin: Targeted drug companion diagnosis for tumor tissue samples based on NGS technology platform. The whole exon region and partial intron of nearly 600 tumor related genes can be fully covered and rapidly detected by the technology of target segment capture, given targeted medication guidance and the chemotherapy sensitive tips.                                         

2223.jpgAikeyin I:                                                                                   

Comprehensive: disposable detection of ~600 tumor related genes, covering almost all tumor related genes and all targeted drug sites; 

Accurate: repeat detection of more than 1000 times per locus, error rate less than 1%. 

2223.jpgAikeyin II: a one-time detection of nearly 70 of the currently known and highly related cancer genes; each locus is repeated more than 1000 times, error rate less than 1%.               


Si Yueyin:  Non-invasive NGS testing for cancer patients with blood samples of ctDNA.  Accurate detection of DNA gene in exon region and partial intron region of nearly 600 tumor related genes by target segment capture.  It can be used to guide the targeted therapy of ctDNA in patients with inoperable advanced tumor and the detection of genes related to radiotherapy and chemotherapy.

2223.jpgSiyueyin I:                                                                                 

Comprehensive: disposable detection of nearly 600 tumor related genes, covering almost all tumor related genes and all targeted drug sites. 

Accurate: repeat detection of more than 10000 times per locus, error rate less than 1%.   

Noninvasive: capture tumor DNA directly from the peripheral blood, to avoid traumatic tissue biopsy.  

2223.jpgSiyueyin II: a one-time detection of  ~ 70 of the currently known and highly related cancer genes 

Toxicity Evaluation

ColoTox:Based on the detection of germline DNA, ~21SNPs on DPYD and TYMS/ENSOF1  were detected, and the algorithm was used to provide the prediction of individual 5-FU toxicity.                   

1493706400479151PwxC.jpg5-FU monotherapy or combination therapy are most popular cheotherapy in CRC, 90% patients need intravenous or oral use 5-FU or Xeloda;

1493706400479151PwxC.jpgHowever, patients with 20-30% have severe side effects and nearly 10% of patients need to be hospitalized for the side effects;

1493706400479151PwxC.jpgColoTox help to diagnosis the toxicity of 5-FU in patients with colorectal cancer before neoadjuvant therapy or adjuvant therapy, and to provide a safe dose. Some patients are even recommended not to use 5-FU to avoid fatal toxicity.

1493706400479151PwxC.jpgTest developed by Oxford Cancer Biomarkers company , based on the genome-wide association study GWAS developed the relevent SNPs Panel, and has completed clinical validation of N=1200.

Drug Resistance

Si Yueyin:Non-invasive NGS testing for cancer patients with blood samples of ctDNA.  Accurate detection of DNA gene in exon region and partial intron region of nearly 600 tumor related genes by target segment capture. A comprehensive and accurate grasp of new mutations in the tumor, in particular, it can be used to detect the presence of drug-resistant sites in patients during treatment, so as to reverse the disease in a reversible phase by changing the treatment.                                                      

1493706400479151PwxC.jpgKRAS mutations in patients with KRAS wild-type normally occured in 5-6 months after EGFR inhibitors  treatment, leading to treatment resistance and failure;    

1493706400479151PwxC.jpgMultiple mechanisms of resistance to EGFR monoclonal antibodies existed, related to EGFR mutation / amplification, KARS mutation / amplification, BRAF mutation / amplification, NRAS mutation, HER2 mutation, PIK3CA mutation, MET amplification, MYC amplification, NOTCH amplification, etc. 

1493706400479151PwxC.jpgTherefore, it is recommended not to be limited to a single gene or a few known single or multiple SNPs for resistance monitoring.More extensive testing can be used to identify patients at the time of treatment with drug resistance sites, while providing a new target for drug testing in order to reverse the reversibility of the disease in a reversible phase by changing the treatment.

Technology Platform
Illumina HiSeqSNP polymorphism detectionDigital pathologyMolecule pathology
PCRGene liquid biopsyWhole Exon sequencingGene bank data analysis

Service Protocol

流程.jpg

TOP